PI4K
PI4K (phosphatidylinositol 4-kinase) catalyzes the first committed steps for phosphatidylinositol 4,5-bisphosphate biosynthesis. It is associated with viral replication and cancer.
Products Related to PI4K(15)
- GC30777PI4KIIIbeta-IN-10CAS: 1881233-39-1Purity: >99.50%
PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC50 of 3.6 nM.
- GC32163BQR-695 (NVP-BQR695)CAS: 1513879-21-4Purity: >99.50%
BQR-695 (NVP-BQR695) is a PI4KIIIβ inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.
- GC32199T-00127_HEV1CAS: 900874-91-1Purity: >98.00%
T-00127_HEV1 is a phosphatidylinositol 4-kinase III beta (PI4KB) inhibitor with an IC50 of 60 nM.
- GC32847PI4KIIIbeta-IN-9CAS: 1429624-84-9Purity: >99.00%
PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC50 of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and PI3Kγ with IC50s of 152 nM and 1046 nM, respectively.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC27959 | NC03 | 568558-66-7 | >98.50% | |
NC03 is a PI4K2A inhibitor and reducing agent. NC03 inhibits the activity of PI4K2A, thereby reducing the production of PI4P in the cellular compartments where PI4K2A functions. | ||||
| GC13089 | PIK-93 | 593960-11-3 | >99.00% | |
PI3Kγ/PI4KIIIβ/PI3Kα inhibitor | ||||
| GC15508 | PI4KIII beta inhibitor 3 | 1245319-54-3 | >99.00% | |
| GC18164 | UCB9608 | 1616413-96-7 | >99.00% | |
PI4KIIIβ inhibitor | ||||
| GC30777 | PI4KIIIbeta-IN-10 | 1881233-39-1 | >99.50% | |
PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC50 of 3.6 nM. | ||||
| GC32118 | KDU691 | 1513879-19-0 | >99.50% | |
An antimalarial compound | ||||
| GC32163 | BQR-695 (NVP-BQR695) | 1513879-21-4 | >99.50% | |
BQR-695 (NVP-BQR695) is a PI4KIIIβ inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively. | ||||
| GC32199 | T-00127_HEV1 | 900874-91-1 | >98.00% | |
T-00127_HEV1 is a phosphatidylinositol 4-kinase III beta (PI4KB) inhibitor with an IC50 of 60 nM. | ||||
| GC32381 | BF738735 | 1436383-95-7 | >99.00% | |
BF738735 is a phosphatidylinositol 4-kinase III beta (PI4KIIIβ) inhibitor with an IC50 of 5.7 nM. | ||||
| GC32847 | PI4KIIIbeta-IN-9 | 1429624-84-9 | >99.00% | |
PI4KIIIbeta-IN-9 is a potent PI4KIIIβ inhibitor with an IC50 of 7 nM. PI4KIIIbeta-IN-9 also inhibits PI3Kδ and PI3Kγ with IC50s of 152 nM and 1046 nM, respectively. | ||||
| GC38033 | KDU731 | 1610610-48-4 | >98.00% | |
KDU731, an orally active C. | ||||
| GC39155 | PI-273 | 925069-34-7 | >98.00% | |
PI-273 is a substrate-competitive and specific phosphatidylinositol 4-kinase IIα (PI4KIIα) inhibitor (IC 50= 0.47μM). | ||||
| GC62109 | MMV390048 | 1314883-11-8 | >99.00% | |
MMV390048 is a representative of a new chemical class of Plasmodium PI4K inhibitor (Kdapp=0.3 ?M). | ||||
| GC65309 | GSK-F1 | 1402345-92-9 | >95.00% | |
GSK-F1 (Compound F1) is an orally active PI4KA inhibitor with pIC50 values of 8.0, 5.9, 5.8, 5.9, 5.9 and 6.4 against PI4KA, PI4KB, PI3KA, PI3KB, PI3KG and PI3KD, respectively. | ||||
| GC72785 | PI4K-IN-1 | 1800017-49-5 | >98.00% | |
PI4K-IN-1 (compound 44) is a potent PI4KIII inhibitor, with pIC50 values of 9.0 and 6.6 for PI4KIIIα and PI4KIIIβ, respectively. | ||||